混合重症监护病房中肾脏清除增强的发生时间与持续时间
该回顾性研究纳入2019年1月至2022年6月一家三级急诊医院ICU的2592例危重患者,选取其中连续测量尿肌酐清除率的患者(n=734),用Kaplan-Meier曲线分析肾脏清除增强(ARC)的发生时间与持续时间。ARC患病率为33.4%(245/734),约半数在入院3天内发生,多数其余病例在1周内发生,持续时间的异质性很大(中位5天),部分超过1个月。多因素分析发现年轻、男性、入院时血肌酐较低、中枢神经系统疾病入院、无既往病史、使用机械辅助通气及使用血管升压药是与ARC发生相关的因素;年轻及ARC第1天尿肌酐清除率较高与ARC持续相关。ARC发生与死亡率降低显著相关,但ARC持续与无ICU天数减少显著相关。
要点
- ARC患病率为33.4%(245/734),约半数病例在入院3天内发生,其余多数在1周内发生。
- ARC持续时间的异质性很大(中位5天),部分病例持续超过1个月。
- 与ARC发生相关的因素包括:年轻、男性、入院时血肌酐较低、中枢神经系统疾病入院、无既往病史、使用机械辅助通气及使用血管升压药。
- 与ARC持续相关的因素包括年轻和ARC第1天尿肌酐清除率较高。
- ARC发生与死亡率降低显著相关,但ARC持续与无ICU天数减少显著相关;对于预测会持续ARC的患者,作者认为可能需要考虑从早期开始对经肾排泄药物采用长期增加剂量的方案。
适用人群与场景
- 2019年1月至2022年6月一家三级急诊医院ICU收治的危重患者,从2592例患者中选取连续测量尿肌酐清除率者(n=734)进行观察。
处置流程与药物剂量
- 对于预测会持续ARC的患者,作者认为可能需要考虑从早期开始对经肾排泄药物采用长期增加剂量的方案。
研究设计与关键结果
- 研究类型:回顾性研究,数据来自2019年1月至2022年6月一家三级急诊医院ICU的2592例危重患者病历,其中734例连续测量尿肌酐清除率者纳入分析。
- ARC患病率为33.4%(245/734);约半数病例在入院3天内发生ARC,其余多数在1周内发生。
- ARC持续时间异质性很大(中位5天),部分病例持续超过1个月。
- 多因素分析:与ARC发生相关的因素包括年轻、男性、入院时血肌酐较低、中枢神经系统疾病入院、无既往病史、使用机械辅助通气及使用血管升压药。
- 与ARC持续相关的因素包括年轻和ARC第1天尿肌酐清除率较高。
- ARC发生与死亡率降低显著相关,但ARC持续与无ICU天数减少显著相关。
证据类型、等级与局限
- 证据类型:回顾性研究;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于预测会持续ARC的患者,可能需要考虑从早期开始对经肾排泄药物采用长期增加剂量的方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Augmented renal clearance (ARC) is associated with lower blood plasma concentrations of renally excreted drugs; however, its time course is unknown. The current study aimed to determine the onset timing/duration of ARC, its risk factors, and its association with clinical outcomes by continuous monitoring of urinary creatinine clearance (CrCl) in critically ill patients.
METHODS: Data were retrospectively obtained from the medical records of 2592 critically ill patients admitted to the intensive care unit (ICU) from January 2019 to June 2022 at a tertiary emergency hospital. Among these, patients with continuously measured urinary CrCl were selected and observed over time. We evaluated the onset timing and duration of ARC by plotting Kaplan-Meier curves. Furthermore, by multivariate analyses, factors associated with the onset and persistence of ARC were analyzed, and the association between the ARC time course and clinical outcomes was evaluated.
RESULTS: The prevalence of ARC was 33.4% (245/734). ARC onset was within 3 days of admission in approximately half of the cases, and within 1 week in most of the other cases. In contrast, the persistence duration of ARC varied widely (median, 5 days), and lasted for more than a month in some cases. Multivariate analysis identified younger age, male sex, lower serum creatinine at admission, admission with central nervous system disease, no medical history, use of mechanically assisted ventilation, and vasopressor use as onset factors for ARC. Furthermore, factors associated with ARC persistence such as younger age and higher urinary CrCl on ARC day 1 were detected. The onset of ARC was significantly associated with reduced mortality, but persistent of ARC was significantly associated with fewer ICU-free days.
CONCLUSIONS: Despite the early onset of ARC, its duration varied widely and ARC persisted longer in younger patients with higher urinary CrCl. Since the duration of ARC was associated with fewer ICU-free days, it may be necessary to consider a long-term increased-dose regimen of renally excreted drugs beginning early in patients who are predicted to have a persistent ARC.
参考来源
- Mikami R, Hayakawa M, Imai S, et al. Onset timing and duration of augmented renal clearance in a mixed intensive care unit. J Intensive Care. 2023. PMID: 36959656. doi:10.1186/s40560-023-00660-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。